These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2261942)

  • 1. Verapamil in antihypertensive treatment of patients on renal replacement therapy--clinical implications and pharmacokinetics.
    Beyerlein C; Csaszar G; Hollmann M; Schumacher A
    Eur J Clin Pharmacol; 1990; 39 Suppl 1():S35-7. PubMed ID: 2261942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study.
    Speders S; Sosna J; Schumacher A; Pfennigsdorf G
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S47-9. PubMed ID: 2475686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive efficacy of sustained-release verapamil.
    Zachariah PK; Sheps SG; Oshrain C; Schirger A; Stein WJ
    J Clin Hypertens; 1987 Dec; 3(4):536-46. PubMed ID: 3330987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of isolated systolic hypertension in the elderly with verapamil slow-release 240 mg.
    Böhmer F; Barousch R; Reinfrank J
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S45-6. PubMed ID: 2475685
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of mild to moderate hypertension with verapamil slow-release in outpatients. Collaborative Group of the Spanish League for the Fight Against Hypertension.
    Gómez Pajuelo C; Pérez Naranjo J; Ruiz Martínez I
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S50-2. PubMed ID: 2475687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effects of slow-release verapamil in relation to plasma concentration in aged hypertensives. A study with continuous monitoring of arterial pressure and electrocardiogram].
    Canonico V; Bonaduce D; De Caprio L; Nicolino A; Forgione L; Petretta M; Rengo F
    G Ital Cardiol; 1990 Oct; 20(10):924-32. PubMed ID: 2090531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of a slow channel inhibitor, verapamil, in the management of hypertension.
    Gould BA; Mann S; Kieso H; Balasubramanian V; Raftery EB
    Clin Exp Pharmacol Physiol Suppl; 1982; 6():113-21. PubMed ID: 6956472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new sustained-release formulation of verapamil in the treatment of hypertension.
    Midtbo KA; Hals O; Lauve O
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):125S-132S. PubMed ID: 3540222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verapamil versus nifedipine in slow-release preparations for the treatment of mild to moderate hypertension.
    Shamiss A; Meisel S; Nussinovitch N; Rosenthal T
    J Hum Hypertens; 1990 Aug; 4(4):465-8. PubMed ID: 2258895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive blood pressure monitoring evaluation of verapamil slow-release 240-mg antihypertensive effectiveness.
    Novo S; Alaimo G; Abrignani MG; Longo B; Muratore G; Strano A
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S38-41. PubMed ID: 2475683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sustained-release verapamil: automatic ambulatory blood pressure monitoring.
    Zachariah PK; Sheps SG; Schriger A
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):133S-142S. PubMed ID: 3540223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension.
    Fuenmayor NT; Faggin BM; Cubeddu LX
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S53-6. PubMed ID: 2475688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related antihypertensive and haemodynamic effects of verapamil SR: clinical results and effects on atrial natriuretic peptide.
    Antonicelli R; Tomassini PF; Galletti P; Gambini C; Marini M; Amadio L; Paciaroni E
    Eur J Clin Pharmacol; 1990; 39 Suppl 1():S29-33. PubMed ID: 2148149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of verapamil on home self-measurement of blood pressure and heart rate by hypertensive patients. Verapamil-Frequency Research Group.
    Fernández-González R; Gómez-Pajuelo C; Gabriel R; de La Figuera M; Moreno E; of The Verapamil-Frequency Res
    Blood Press Monit; 2000 Feb; 5(1):23-30. PubMed ID: 10804447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of enalapril and sustained-release verapamil in older patients with mild to moderate essential hypertension.
    Weir MR; Cassidy CA; Hall PS; Lancaster A; Schubert C; Urick A; Saunders E; Kong BW; Jenkins P; Lavin PT
    Clin Ther; 1990; 12(2):139-48. PubMed ID: 2354483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension.
    White WB; Elliott WJ; Johnson MF; Black HR
    J Hum Hypertens; 2001 Feb; 15(2):135-41. PubMed ID: 11317194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum ionized calcium--a predictor of therapeutic response to slow calcium channel blockade in essential hypertension.
    Midtbø K; Hals O
    Angiology; 1987 Nov; 38(11):841-6. PubMed ID: 3688552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verapamil sustained-release in renal parenchymal hypertension: effect on blood pressure, kidney function, angiotensin II, aldosterone, arginine vasopressin, atrial natriuretic peptide, and lipoproteins.
    Eiskjaer H; Pedersen EB; Rasmussen LM; Jespersen B
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S17-22. PubMed ID: 2475677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium intake does not influence the effect of verapamil in hypertensive patients with mild renal insufficiency.
    Ruilope LM; Casal MC; Guerrero L; Alcázar JM; Férnandez ML; Lahera V; Rodicio JL
    Drugs; 1992; 44 Suppl 1():94-8. PubMed ID: 1283591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between verapamil plasma concentrations and its antihypertensive action.
    Gonzalez-Gomez A; Cires Pujols M; Gamio Capestany F; Rodriguez de la Vega A; Garcia-Barreto D
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):453-60. PubMed ID: 3198301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.